Krystal Biotech, Inc. (NASDAQ: KRYS) Starts Presentation at 30th Annual ROTH Conference
Krystal Biotech (NASDAQ: KRYS) is a gene therapy company focused on developing and commercializing novel treatments for patients suffering from dermatological diseases. The company’s lead product candidate, KB103, is currently in preclinical development and seeks to use gene therapy to treat Epidermolysis Bullosa. KB103 has been engineered employing the company’s STAR platform to deliver functional human COL7A1 genes directly to the patients’ dividing and non-dividing skin cells. The company’s pipeline also includes therapies in development to treat Netherton Syndrome, Ichthyosis Vulgaris, and Atopic Dermatitis. For more information, visit the company’s website at www.krystalbio.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial…







